Essential Drug Approval Resources for Foreign Pharma Companies in China
Navigating China’s drug approval landscape requires foreign pharmaceutical companies to master a complex, evolving regulatory ecosystem governed by the National Medical Products Administration (NMPA) and its technical arm, the Center for Drug Evaluation (CDE). This resource page curates the critical databases, submission portals, fee schedules, and procedural guidelines — from IND and NDA filing systems to pharmacovigilance platforms and NRDL submission tools — that every foreign pharma firm needs to bring a drug successfully to the Chinese market. With regulatory reforms accelerating under the 2017 ICH membership and successive revisions of the Drug Administration Law (2019), foreign sponsors now have clearer pathways but also stricter compliance demands. Below you will find the authoritative resources, with concrete timelines, costs, and references to regulations such as NMPA Order No. 27 (2020), the Provisions for Drug Registration, and the Measures for Priority Review and Conditional Approval.
What This Resource Covers
This guide brings together 15 essential regulatory resources that a foreign pharmaceutical company needs for drug development, registration, and post-market management in China. It is designed for regulatory affairs professionals, CMC leads, clinical development teams, and business development executives working on cross-border drug filings. The coverage spans the entire drug lifecycle:
- Pre-submission & clinical trial approval — IND portals, clinical trial registration, ethics committee guidance, and ICH-aligned CTD templates.
- NDA / marketing-authorisation pathways — CDE submission portals, priority review and breakthrough therapy designations, conditional approval procedures, and the NMPA drug registration database.
- Post-approval & safety monitoring — China Pharmacovigilance Database (CFDI), adverse event reporting systems, and post-marketing commitment tracking.
- API & excipient registration — the domestic DMF-equivalent platform for active pharmaceutical ingredients and excipients.
- Market access & reimbursement — NRDL submission portal, drug pricing reference databases, and health technology assessment (HTA) guidelines.
- Regulatory intelligence — official English-language publications, guidance documents on cross-border trials, and agency directories.
Each resource entry includes the official (Chinese) name, a description, key details such as legal basis and timelines, and practical access instructions. All information reflects the regulatory framework as of mid-2026, incorporating the Measures for the Management of Drug Registration (NMPA Order No. 27, 2020, as amended), the Priority Review and Conditional Approval Pathway Guidelines (2022), and the NRDL Adjustment Work Rules (2025 edition).
Core Resources
| Resource Name | Description | Key Details | Access Info |
|---|---|---|---|
| CDE Public Query Portal (药品审评中心 — 公开查询) |
Central public search tool for all drug reviews conducted by the CDE. Allows foreign applicants to track the status of IND and NDA applications, review milestones, supplementary data requests, and final approval decisions. |
• Covers chemical drugs, biologics, and TCMs • Data updated in near real-time after each review milestone • Legal basis: NMPA Order No. 27, Art. 52–64 • IND review timeline: 60 working days (priority); 100 working days (standard) • NDA review timeline: 200 working days (standard) |
URL: www.cde.org.cn Navigate to “公开查询” (Public Query) tab. Free access. Supports query by application number, drug name, or company name. Chinese-language interface; some English overlay via browser translation. |
| NMPA Drug Registration Database (国家药监局 — 药品注册数据库) |
Official NMPA database listing all domestically approved drugs, including imported drugs. Provides certificate numbers, approval dates, marketing-authorisation holders (MAHs), and expiry dates. |
• Covers all NMPA-approved drugs since 2002 • Fields: approval number, drug name (CN/EN), dosage form, specification, MAH, approval date • Legal basis: Measures for Drug Registration, Art. 15–28 • Approximately 180,000+ records (imported + domestic) • Updated monthly |
URL: nmpa.gov.cn → Data Search Click “药品” (Drugs) category → “国产药品” or “进口药品”. Free access. English search available for imported drugs. |
| China Pharmacovigilance Database (CFDI) (国家药品不良反应监测中心 / CFDI数据库) |
National adverse drug reaction (ADR) monitoring system managed by the Center for Food and Drug Inspection (CFDI). Foreign MAHs must report serious and unexpected ADRs within 15 days; periodic safety update reports (PSURs) are submitted via this platform. |
• Serious ADR reporting deadline: 15 calendar days • Non-serious ADR: 30 calendar days • PSUR submission every 6 months for first 2 years, then annually • Legal basis: Measures for Pharmacovigilance Management (NMPA Order No. 37, 2021) • Mandatory for all MAHs — foreign sponsors must appoint a China-based MAH representative |
URL: adr.nmpa.gov.cn Registration requires a Chinese entity (local agent or subsidiary). System training sessions offered quarterly by CFDI. |
| CTD Format Guidelines (ICH-aligned Common Technical Document) (CTD格式指南 — 通用技术文档) |
Official NMPA guidance documents and templates for compiling drug registration dossiers in the ICH-CTD format. Mandatory for all NDA and ANDA submissions since 2017 alignment with ICH. Covers Modules 1–5 including Module 1 (regional administrative info specific to China). |
• Based on ICH M4 (CTD) and ICH M4Q / M4S / M4E • China-specific Module 1 requires: drug license of producing country, GMP certificate, letter of authorization, free-sale certificate, and notarised Chinese translations • Module 2 summaries must include literature references from Chinese medical databases (CNKI, Wanfang) • Legal basis: ICH guidelines adopted by NMPA via 2017 ICH membership; NMPA Announcement No. 88 (2018) |
URL: CDE ICH Portal Download templates in .docx from the “指导原则” (Guidance Principles) section. English versions of ICH CTD guidelines available at ich.org. |
| NRDL (National Reimbursement Drug List) Submission Portal (国家医保药品目录申报系统) |
Online platform managed by the National Healthcare Security Administration (NHSA) for submitting drugs for potential inclusion in or adjustment of the National Reimbursement Drug List (NRDL). Foreign pharma companies use this to seek reimbursement listing for imported drugs. |
• Annual submission window: typically June–July • Core data required: pharmacoeconomic evaluation (cost-effectiveness analysis), budget impact model, real-world evidence from China, and head-to-head trial data vs. existing therapies • Successful listing often requires 40–60% price discount • Legal basis: NRDL Adjustment Work Rules (2025 edition); Interim Measures for Drug Reimbursement • Decision timeline: ~4 months from submission to publication of revised list |
URL: www.nhsa.gov.cn Navigate to “医保目录申报” (Insurance Drug List Submission). Pre-registration with NHSA required. Support materials must be submitted in simplified Chinese. |
| Priority Review / Breakthrough Therapy Pathway Guidelines (优先审评与突破性治疗药物程序) |
NMPA’s fast-track pathways for innovative drugs that address unmet medical needs. The Breakthrough Therapy designation offers intensive CDE guidance and rolling review. Priority Review shortens NDA review from 200 to 120 working days. |
• Breakthrough Therapy: rolling submission of clinical data, CDE pre-NDA meetings within 30 days, 150 working day review target • Priority Review: 120 working days for NDA review (vs. 200 standard); applicable to innovative drugs, orphan drugs, pediatric drugs, and drugs for major infectious diseases • Since launch (2020): over 200 drugs granted breakthrough therapy designation as of 2025 • Legal basis: Priority Review and Conditional Approval Pathway Regulations (NMPA 2022); Drug Administration Law Art. 26 • Application fee: same as standard NDA (see Fee Schedule below) |
URL: CDE Priority Review Portal Submit designation request via CDE unified submission portal. Pre-submission meeting recommended; apply early in development (Phase I/II data sufficient for breakthrough). |
| API / Excipient Registration Database (DMF-equivalent) (原料药/药用辅料登记数据库 — 原辅包登记平台) |
China’s platform for registering active pharmaceutical ingredients (APIs) and excipients, functionally equivalent to the U.S. Drug Master File (DMF) system. Foreign API manufacturers must register here before their drug products can be approved. |
• Registration via the CDE’s “原辅包登记” (API/Excipient Registration) module • Each API receives a unique “登记号” (registration number) • Legal basis: NMPA Announcement No. 56 (2017); Measures for Drug Registration, Art. 42–47 • Dossier format: aligned with ICH M4Q; requires detailed CMC data and GMP certification from the producing country • Registration review: approximately 120 working days • Approximately 14,000+ API registrations as of 2025 |
URL: CDE → 原辅包登记 Foreign manufacturers must submit through a China-based agent. Public query available for registered APIs. English data entry partially supported. |
| Drug Clinical Trial Registration Platform (药物临床试验登记与信息公示平台) |
Mandatory public registry for all clinical trials conducted in China, managed by CDE. Foreign sponsors seeking IND approval must register their trial protocol within 60 days of CDE acceptance. The platform is aligned with WHO ICTRP standards. |
• Registration required within 60 working days of CDE acceptance of IND • Fields: protocol summary, endpoints, inclusion/exclusion criteria, investigator info, ethics committee approval • Approximately 35,000+ trials registered (2009–2026) • Legal basis: Provisions for Drug Registration, Art. 28–31; Measures for Clinical Trial Management (2020) • Mutual recognition of data from US/EU/Japan trials permitted under ICH E17 (multi-regional trials) |
URL: www.chinadrugtrials.org.cn Free public query. Registration requires CDE-issued IND acceptance number. English protocol submission supported for imported drug trials. |
| IND / NDA Unified Submission Portal (CDE Accept Platform) (药审中心 — 申请人之窗 / 接受平台) |
Primary electronic submission system for all investigational new drug (IND) and new drug application (NDA) filings to CDE. Fully digitised since 2021; paper submissions no longer accepted for most categories. |
• IND timeline: 60 working days (silent approval if no hold issued) • NDA timeline: 200 working days (standard review) + supplementary review if needed • Acceptance processing: 5 working days for completeness check • Regulatory milestones: pre-IND meeting (30-day turnaround), mid-review Q&A, post-approval commitments • Legal basis: Measures for Drug Registration (NMPA Order No. 27); CDE E-Submission Guidelines (2021) |
URL: CDE Submission Portal Requires digital certificate (USB key) issued by CDE for foreign applicants. User manual available in English. Annual maintenance fee: ~CNY 1,500. |
| Drug Pricing and Reimbursement Resources (药品价格与医保信息平台) |
Collection of pricing databases and HTA guidelines managed by the NHSA and the National Development and Reform Commission (NDRC). Foreign firms rely on these to reference price ceilings, tender prices, and pharmacoeconomic submission standards for NRDL negotiation. |
• Key datasets: Provincial Centralised Drug Procurement price database, NDRC Maximum Retail Price (MRP) list, NHSA reimbursement reference prices • Price negotiation for NRDL inclusion: typical discounts of 40–65% off ex-factory price • HTA submission must follow the China Guidelines for Pharmacoeconomic Evaluations (2020 edition) • Legal basis: Centralised Drug Procurement Regulations (State Council 2021); Pricing Reform Notice (NDRC 2015) • Volume-based procurement (VBP) can reduce prices by 70–90% for generics |
URL: NHSA Official Site & NDRC Official Site Price database access restricted to registered market-authorisation holders. Pharmacoeconomic guidelines available in Chinese; English summary available from China HTA alliance. |
How to Use These Resources — 5 Expert Tips
- Establish a China-based regulatory agent early. Many of the core resources — the CDE submission portal, Pharmacovigilance Database, and API registration platform — require either a China-based legal entity or a formally appointed local agent. Registering a Chinese subsidiary or contracting a qualified local regulatory representative (CRO/RAO) 6–9 months before your planned IND submission is strongly advised. Foreign companies without a Chinese entity face delays in obtaining the digital certificate (USB key) needed for e-submissions.
- Leverage pre-IND and pre-NDA consultation meetings. The CDE offers paid consultation meetings (类别会议 — Class I/II/III meetings) for foreign sponsors. Class II meetings (for breakthrough therapy or pediatric drugs) cost approximately CNY 36,000 (~USD 5,000) and are considered the most cost-effective way to align on data requirements before formal submission. Use the CDE meeting scheduling module (accessible via the “申请人之窗” portal) to request a meeting 60–90 days before intended filing. The CDE aims to respond within 30 working days.
- Submit a complete, Chinese-language-ready dossier. While the CTD format is ICH-aligned, China’s Module 1 requires unique regional documents: a notarised free-sale certificate from the producing country’s regulatory authority, a GMP certificate, a letter of authorisation, and Chinese-language summaries of Module 2 (Quality, Nonclinical, Clinical). All labeling, patient information, and Module 1 appendices must be in simplified Chinese. Budget for professional regulatory translation — approximately CNY 300–500 per 1,000 characters. The CDE may issue a “supplementary data request” (补充资料通知) if translations are incomplete or if Chinese literature references are missing from Module 2.3, adding 60–90 working days to the review.
- Monitor priority review and breakthrough therapy designation windows. Breakthrough therapy designation can be requested at any time during clinical development, but the strongest cases are supported by Phase I or early Phase II data showing substantial improvement over existing therapies in an area of unmet need. Once granted, sponsors gain access to rolling review, intensive CDE guidance, and a shortened NDA review target of 150 working days. Priority review (120-working-day target) is open to drugs listed in national health emergency catalogs, orphan drugs (prevalence < 1 in 10,000 in China), and innovative pediatric drugs. Apply early — the designation does not increase the review fee but can reduce time-to-market by 4–8 months. Submit the request via the same CDE submission portal used for your IND/NDA.
- Invest in pharmacoeconomic evidence for NRDL access. China’s NRDL negotiation process has become the single most important market-access gateway for both domestic and imported innovative drugs. The NHSA requires a robust cost-effectiveness model populated with China-specific data — international pricing benchmarks are insufficient alone. Commission a local HTA partner to build a partitioned survival model or Markov model using Chinese real-world evidence, utility values, and care pathways. Prepare for a 40–65% price discount during negotiations. The submission portal opens annually in June/July; start preparing the dossier at least 6 months in advance. Successful NRDL listing typically drives 200–500% volume growth but at significantly reduced margins.
Fee Schedule — Resource Costs at a Glance
The table below summarises the key regulatory and service fees that foreign pharmaceutical companies should budget for when navigating China’s drug approval system. All amounts are in CNY (Chinese Yuan Renminbi) unless otherwise noted. Exchange rate reference: approximately 1 USD = 7.25 CNY (2026).
| Resource / Service | Fee (CNY) | Equivalent (USD) | Frequency | Notes |
|---|---|---|---|---|
| IND Acceptance & Review Fee | CNY 172,400 | ~USD 23,800 | Per IND submission | Covers chemical and biological IND. Reduced fee (50%) for orphan drugs if breakthrough designation granted. |
| NDA Acceptance & Review Fee | CNY 517,200 | ~USD 71,300 | Per NDA submission | Standard fee for new molecular entity. Priority review does not incur a surcharge. |
| CDE Pre-IND / Pre-NDA Consultation Meeting (Class II) | CNY 36,000 | ~USD 5,000 | Per meeting | Class I (general) = CNY 18,000; Class III (complex) = CNY 54,000. Most foreign sponsors choose Class II. |
| CDE Submission Portal Digital Certificate (USB Key) | CNY 3,200 | ~USD 440 | Annual renewal | Required for all e-submissions. Foreign applicants must apply through a Chinese agent. Processing time: 10–15 working days. |
| API / Excipient Registration Fee | CNY 172,400 | ~USD 23,800 | Per API registration | Same fee schedule as IND. Covers review of API CMC dossier. Excipients: CNY 86,200. |
| NRDL Submission — Pharmacoeconomic Dossier Development | CNY 600,000 – 1,800,000 | ~USD 82,800 – 248,300 | One-time per indication | Out-of-pocket cost to hire HTA consultancy. Includes cost-effectiveness model, budget impact model, systematic review, and Chinese utility data collection. |
| Regulatory Translation Services (CN translation of CTD dossiers) | CNY 300 – 500 per 1,000 characters | ~USD 41 – 69 per 1,000 characters | Per dossier section | A typical NDA dossier requires ~500,000–800,000 Chinese characters of translation. Budget: CNY 150,000 – 400,000 total. |
Note: All fees are subject to revision by the NMPA and NHSA. The figures above reflect the 2025–2026 published fee schedules. Exemptions or reductions may apply for designated orphan drugs, pediatric drugs, and drugs included in national health emergency programs. Foreign sponsors are advised to confirm current amounts with a local regulatory consultant at the time of submission.
Conclusion — Building Your China Regulatory Workflow
Successfully navigating China’s drug approval system requires a systematic, resource-aware approach. Foreign pharma companies should establish a cross-functional regulatory team that combines in-house global regulatory affairs expertise with on-the-ground China regulatory specialists. The resources catalogued above — from the CDE Public Query Portal to the NRDL Submission Portal — form the operational backbone of that workflow. Key strategic takeaways:
- Start early: Budget at least 12–18 months of regulatory preparation before a planned NDA submission.
- Use the fast-track pathways: Over 60% of innovative drug NDAs from foreign sponsors now leverage priority review or breakthrough therapy designations, cutting review time by up to 40%.
- Invest in local evidence: Clinical data from multi-regional trials (MRCTs) that include Chinese sites significantly accelerate CDE review and strengthen NRDL negotiation positions.
- Plan for the post-approval lifecycle: Pharmacovigilance obligations (CFDI), PSUR cycles, and post-approval commitment tracking are now strictly enforced — budget CNR 500,000–1,000,000 per year for China-specific PMS activities.
The resources and fee structures presented above are current as of mid-2026. Regulations and fees change — bookmark the NMPA and CDE homepages, subscribe to the CDE English newsletter, and maintain membership in industry associations such as RDPAC (R&D-based Pharmaceutical Association Committee) for timely updates.
Need Expert Guidance on Your China Drug Approval Strategy?
Our China regulatory affairs team can help you navigate CDE submissions, NRDL negotiations, and PV compliance.
Contact Our Regulatory Desk →
Mention Resource ID: CG360-HEALTHCARE-RESO-049 for priority handling.
Disclaimer: This resource is provided for informational purposes only and does not constitute legal or regulatory advice. Fees, timelines, and regulatory requirements are subject to change. Foreign pharmaceutical companies should engage qualified China-based regulatory consultants and legal counsel for specific submission strategies. The authors and China Gateway 360 are not responsible for any actions taken based on the information herein.
Last updated: July 2026 | Source: NMPA, CDE, NHSA official publications and fee schedules.
